2000 Participants Needed

Smoking Cessation Interventions for Quitting Smoking

Recruiting at 2 trial locations
SF
Overseen BySteven Fu, MD, MSCE
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of Minnesota
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to help people of color who smoke quit by testing different ways to connect them with support services. It will compare two approaches: Longitudinal Proactive Outreach (LPO), which offers regular follow-ups and tailored support calls, and Ask-Advice-Connect (AAC), which provides enhanced regular care. The trial focuses on individuals who have smoked at least once in the last month and are part of the Hennepin Healthcare or MCHS system. Participants should be able to communicate in English or Spanish and have their contact information listed in their health records.

As an unphased trial, this study offers a unique opportunity to contribute to innovative approaches that may improve smoking cessation support for diverse communities.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that the Ask-Advice-Connect (AAC) approach is generally safe and well-tolerated. Studies have found it effectively helps smokers connect with treatment services, such as quitlines and nicotine replacement therapy, without major safety concerns. This method primarily involves advising smokers to quit and linking them to resources, which is considered low-risk.

Similarly, Longitudinal Proactive Outreach (LPO) safely increases participation in smoking cessation programs. Research indicates that LPO can successfully reach smokers who might not seek help independently. This approach includes regular follow-ups to encourage quitting, without significant negative effects.

Both AAC and LPO support people who want to quit smoking, and both have been studied in various settings with no major safety issues.12345

Why are researchers excited about this trial?

Researchers are excited about these smoking cessation interventions because they offer a new approach by combining Ask-Advice-Connect (AAC) with Longitudinal Proactive Outreach (LPO). Unlike standard care, which often relies on brief counseling and nicotine replacement therapy, the AAC + LPO approach provides ongoing, personalized support through motivational interviewing calls at key intervals—baseline, 3, 6, and 9 months post-enrollment. This ongoing support aims to keep participants engaged and motivated to quit smoking over the long term, potentially increasing success rates compared to traditional methods.

What evidence suggests that this trial's treatments could be effective for smoking cessation among BIPOC populations?

Research has shown that the Ask-Advice-Connect (AAC) approach, which participants in this trial may receive, can significantly increase enrollment in smoking cessation programs. One study found that direct connection to the Quitline resulted in enrollment rates 13 times higher than traditional methods. Additionally, about 16.6% of participants reported quitting smoking after six months.

The Longitudinal Proactive Outreach (LPO), another treatment option in this trial, has also helped more people quit smoking, particularly those who are hard to reach. This proactive approach has been linked to higher quit rates among individuals from various economic backgrounds and has effectively encouraged smokers from disadvantaged groups to use cessation treatments. These findings suggest that both AAC and LPO could be promising methods to help people stop smoking.34678

Who Is on the Research Team?

SF

Steven Fu, MD, MSCE

Principal Investigator

Minneapolis Veterans Affairs Medical Center

Are You a Good Fit for This Trial?

This trial is for BIPOC individuals who are part of the Hennepin Healthcare or MCHS system, speak English or Spanish, currently smoke cigarettes, and want to quit. They must have contact information in their health record. People with cognitive impairments or under legal guardianship, or those who've opted out of research can't participate.

Inclusion Criteria

English or Spanish-speaking BIPOC patients within the Hennepin Healthcare or MCHS system. BIPOC patients are any patients with a chart identified race that is not White, and will be verified by self-report from the baseline survey
Currently smoke more than 1 cigarette over the past 30 days
Must have address or telephone number in the electronic health record

Exclusion Criteria

I have chosen not to participate in any research studies.
My health records show I have cognitive issues or I am under legal guardianship.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive AAC plus an MI tailored outreach call at baseline and at 3, 6, and 9 months post-enrollment, with enhanced access to State Quitline and Nicotine Replacement Therapy

9 months
4 visits (virtual)

Follow-up

Participants are monitored for smoking abstinence and quality of life changes

9 months
3 visits (virtual)

What Are the Treatments Tested in This Trial?

Interventions

  • Ask-Advice-Connect (AAC)
  • Longitudinal Proactive Outreach (LPO)
Trial Overview The study tests two methods to help BIPOC smokers quit: Ask-Advice-Connect (AAC) and Longitudinal Proactive Outreach (LPO). It aims to see if proactive outreach using these methods increases the use of evidence-based cessation treatments compared to standard care.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: AAC + Longitudinal Proactive Outreach (LPO)Experimental Treatment2 Interventions
Group II: Enhanced Usual Care: Ask-Advice-Connect (AAC)Active Control1 Intervention

Ask-Advice-Connect (AAC) is already approved in United States for the following indications:

🇺🇸
Approved in United States as Ask-Advice-Connect for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Minnesota

Lead Sponsor

Trials
1,459
Recruited
1,623,000+

Published Research Related to This Trial

The Ask-Advise-Connect (AAC) approach effectively linked 12% of current smokers at a Federally Qualified Health Center to Quitline services, demonstrating its potential to enhance smoking cessation efforts in low-socioeconomic status communities.
Post-implementation feedback from clinic staff indicated that AAC was easy to implement and positively impacted patient care, suggesting it could become a standard practice for smoking cessation in similar healthcare settings.
The implementation of ask-advise-connect in a federally qualified health center: a mixed methods evaluation using the re-aim framework.Shorey Fennell, B., Cottrell-Daniels, C., Hoover, DS., et al.[2023]
A proactive approach to smoking cessation using motivational interviewing (MI) significantly increased the number of smokers receiving counseling in hospitals, with 87% of smokers receiving intervention compared to only 22% in a reactive approach.
While the proactive strategy showed a trend towards increased smoking cessation rates at 12 months (from 43% to 51%), the difference was not statistically significant, indicating potential benefits that may require further investigation.
Uptake and efficacy of a systematic intensive smoking cessation intervention using motivational interviewing for smokers hospitalised for an acute coronary syndrome: a multicentre before-after study with parallel group comparisons.Auer, R., Gencer, B., Tango, R., et al.[2022]
The implementation of the Ask-Advise-Connect (AAC) method in a rural Tennessee clinic led to a smoking cessation rate of 12.5% among participants, which is above the national average for smoking cessation programs.
Over a 4-month period, the clinic provided 102 counseling visits, and 21% of participants reported a significant decrease in cigarette consumption, highlighting the potential effectiveness of workplace cessation programs.
Tobacco Cessation and Referral to the National Quitline.Blocker, J., Lazear, J., Ridner, SL.[2020]

Citations

Ask Advise Connect: A New Approach to Smoking ...Directly connecting smokers to the Quitline resulted in a 13-fold increase in cessation treatment enrollment when compared to the nationally recommended method ...
quitline treatment engagement and smoking cessation outcomesSelf-reported abstinence at 6 months was 16.6%, and biochemically confirmed abstinence was 4.5%. AAC was successfully implemented as part of ...
Ask-Advise-Connect: A New Approach to Smoking ...Directly connecting smokers to the quitline resulted in a 13-fold increase in cessation treatment enrollment when compared with the nationally ...
Implementation of ask-advise-connect for smoking cessation ...The Ask-Advise-Connect (AAC) approach can help primary care providers to increase the number of people who attempt to quit smoking and enrol into cessation ...
Quitline treatment dose predicts cessation outcomes ...Most smokers received minimal or no treatment, and treatment dose had a large impact on abstinence. Results highlight the importance of improving engagement in ...
Efficacy of Ask Advise Connect in a Safety Net Healthcare ...A strength is that AAC was evaluated in a setting representative of real-world healthcare systems that serve smokers disproportionately burdened by tobacco.
The Ask–Advise–Connect Approach for Smokers in a ...The U.S. Public Health Service recommends that all patients be asked about their smoking at every visit and that smokers be given brief advice to quit and ...
The Ask–Advise–Connect Approach for Smokers in a ...This study evaluated the efficacy of the Ask–Advise–Connect (AAC) approach to linking smokers with treatment in a large, safety net public healthcare system.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security